This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Tempus Labs, Inc.. Active years: 2021-2022.
Company Filing History:
Years Active: 2021-2022
Title: Christine Lo: Innovator in Liquid Biopsy Technology
Introduction
Christine Lo is a prominent inventor based in Chicago, IL (US). She has made significant contributions to the field of liquid biopsy technology, holding 2 patents that focus on innovative methods for cancer diagnostics. Her work is instrumental in advancing the accuracy and efficiency of cancer detection through non-invasive techniques.
Latest Patents
Christine's latest patents include groundbreaking methods and systems for dynamic variant thresholding in a liquid biopsy assay. This invention provides a comprehensive approach for validating somatic sequence variants in subjects with cancer conditions. By obtaining sequence reads from cell-free DNA fragments in liquid biopsy samples, her system aligns these reads to a reference sequence and identifies variant allele fragment counts. The comparison of these counts against a dynamic variant count threshold allows for the validation or rejection of somatic sequence variants based on statistical analysis.
Another notable patent focuses on the estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing. This method involves obtaining sequence reads from a panel-enriched sequencing reaction and determining bin-level coverage ratios. By grouping adjacent bins and fitting segments to integer copy states, the circulating tumor fraction for test subjects can be accurately determined, enhancing the understanding of tumor dynamics.
Career Highlights
Christine Lo is currently employed at Tempus Labs, Inc., where she continues to innovate in the field of genomic medicine. Her work at Tempus Labs emphasizes the integration of technology and data analytics in improving patient outcomes through personalized medicine.
Collaborations
Christine collaborates with talented professionals in her field, including Justin David Finkle and Terri M Driessen. These collaborations foster a dynamic environment for innovation and research, contributing to the advancement of liquid biopsy technologies.
Conclusion
Christine Lo's contributions to liquid biopsy technology exemplify her commitment to improving cancer diagnostics. Her innovative patents and collaborative efforts position her as a leading figure in the field, paving the way for future advancements in cancer detection and treatment.